Saturday 17 October 2026 Export XTNT’s income statement to Excel — free account

Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $133.9 million, up 14.2% from fiscal 2024. In the quarter to June 2026, revenue fell 35.0%, EPS fell 333.3%, free cash flow fell 882.0% and total debt fell 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.28 0.02 −6.67%

Follow XTNT

Alert me

Market cap: $42.5M
P/E: 0.0×
Fwd P/E: −9.1×
Dividend yield: —
F-score: 8/9
Altman Z: 0.03
Beneish M: −3.11
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 12.40%

Capital & Financial Ratios $m

Market Cap 42.48

Revenue 109.53

Net Income (11.14)

Free Cash Flow (0.46)

Net Debt 12.78

Current Ratio 2.16

Debt/Equity 0.57

P/E ratio 0.00

Fwd P/E (9.12)

P/S ratio 0.36

P/B ratio 0.98

Past 5Y EPS Growth —

This Y EPS Growth (183.33%)

Next Y EPS Growth 60.00%

Next Y revenue growth (25.75%)

Next 5Y EPS Growth 81.58%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 24.70%

10-year low 10-year high

P/B against its own 10 years 0.06%

10-year low 10-year high

EV/Sales against its own 10 years 0.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	6	17	10
Receivables	21	21	18	19
Inventory	37	39	30	33
Other	—	—	—	—
	65	67	78	65

	2023	2024	2025	Q'26
Payables	7	8	4	6
ST’ Debt	5	12	14	16
Other	1	1	—	—
	23	29	29	30

Compound Annual Growth %

	10y	5y	3y
Sales	8.48%	20.22%	32.20%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	19.09%	28.55%	14.25%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	23	—	—	—
’25	33	35	33	32	134
’24	28	30	28	32	117
’23	18	20	25	28	91
’22	13	15	14	15	58
’21	13	15	14	14	55
’20	15	11	14	14	53

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(7)	—	—	—
’25	1	1	5	5	13
’24	(6)	(5)	(2)	1	(12)
’23	(2)	(3)	(4)	(1)	(10)
’22	(1)	0	(2)	(2)	(5)
’21	(1)	2	(1)	0	0
’20	(2)	0	0	1	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(7)	—	—	—
’25	0	1	4	5	10
’24	(6)	(6)	(4)	0	(16)
’23	(3)	(3)	(4)	(1)	(11)
’22	(1)	0	(3)	(3)	(7)
’21	(2)	2	(1)	0	(1)
’20	(2)	0	0	0	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	(0.07)	—	—	—
’25	0.00	0.02	0.01	0.00	0.03
’24	(0.03)	(0.03)	(0.04)	(0.02)	(0.12)
’23	(0.02)	(0.02)	0.07	(0.03)	0.01
’22	(0.03)	(0.02)	(0.03)	(0.02)	(0.09)
’21	0.00	(0.01)	(0.02)	(0.03)	(0.06)
’20	(0.19)	(0.19)	(0.10)	(0.01)	(0.25)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.40	3.48	1.61	1.42	0.55	0.56	0.43	0.56	0.33	0.34	Analyst estimates 2026–2028 Powerpack
	High	45.00	14.52	11.50	4.75	3.50	6.58	0.92	1.45	1.31	0.95
People
People	Employees	257	174	166	141	110	118	135	215	232	151
	Revenue/emp, $m	0.35	0.47	0.43	0.46	0.48	0.47	0.43	0.42	0.51	0.89
Income, $m
Income, $m	Revenue	90	83	72	65	53	55	58	91	117	134
	Gross margin, %	69.21	60.65	60.23	65.73	64.48	58.79	55.44	60.75	58.17	62.92
	EBT	(19)	(52)	(70)	(8)	(7)	(5)	(8)	(1)	(16)	7
	EBT margin, %	(21.60)	(63.44)	(97.09)	(12.56)	(12.61)	(8.77)	(14.52)	(1.14)	(13.87)	5.23
	Net income	(19)	(52)	(70)	(8)	(7)	(5)	(8)	1	(16)	5
	Depreciation	7	8	7	3	2	1	1	3	4	5
Per share, $
Per share, $	Revenue	85.23	54.78	6.15	4.91	1.87	0.65	0.62	0.77	0.88	0.96
	Earnings	(18.49)	(33.68)	(5.97)	(0.62)	(0.25)	(0.06)	(0.09)	0.01	(0.12)	0.04
	Cash flow	(13.64)	(0.36)	0.10	(0.03)	(0.03)	0.01	(0.06)	(0.08)	(0.09)	0.09
	Capex	(5.51)	(1.07)	(0.03)	(0.04)	(0.05)	(0.02)	(0.02)	(0.01)	(0.03)	(0.02)
	Free cash flow	(19.15)	(1.43)	0.07	(0.07)	(0.07)	(0.02)	(0.07)	(0.09)	(0.12)	0.07
	Book value	(6.70)	(38.93)	(3.73)	(3.36)	0.51	0.36	0.36	0.43	0.32	0.37
	Shares, m	1	2	12	13	29	85	94	119	134	140
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.12
	P/S	0.08	0.12	0.26	0.33	0.64	0.87	1.09	1.58	0.50	0.81
	P/B	0.00	0.00	0.00	0.00	2.36	1.55	1.84	2.81	1.37	2.14
	EV/Sales	1.50	2.56	2.16	1.43	0.94	0.81	1.00	1.75	0.74	0.87
	EV/FCF	(6.68)	(98.40)	184.45	(96.80)	(24.55)	(31.00)	(8.42)	(14.83)	(5.55)	11.24
Cash, $m
Cash, $m	Operating cash flow	(14)	(1)	1	0	(1)	0	(5)	(10)	(12)	13
	Capex	(6)	(2)	0	(1)	(1)	(2)	(2)	(1)	(4)	(2)
	Free cash flow	(20)	(2)	1	(1)	(2)	(1)	(7)	(11)	(16)	10
Balance, $m
Balance, $m	Working capital	18	14	23	23	6	33	34	42	39	49
	Total debt	131	139	79	77	18	16	16	22	34	25
	Net debt	128	136	72	72	16	(3)	(5)	16	28	8
	Shareholders’ equity	(7)	(59)	(44)	(44)	15	31	34	51	43	51
Returns, %
Returns, %	ROA	(13.67)	(41.96)	(92.16)	(18.36)	(16.60)	(10.09)	(14.77)	0.86	(17.64)	5.29
	ROIC	(3.90)	(30.55)	(134.10)	(5.14)	(1.55)	(8.60)	(14.44)	(9.43)	(10.64)	7.71
	ROE	(2,162.11)	159.37	136.82	18.69	47.31	(21.36)	(26.09)	1.54	(34.88)	10.59

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MDAI Spectral AI, Inc.	$49.6M	— (loss-making)	— (loss-making)	−30.42% (below 0%: shrinking)	n/m	−21.86% (below 0%: shrinking)	31.58%	(122.70%)	Compare
TLIS Talis Biomedical Corporation	$46.3M	— (loss-making)	— (loss-making)	−94.01% (below 0%: shrinking)	n/m	+23.80% (above 0%: growing)	91.78%	0.00%	Compare
SRTS Sensus Healthcare, Inc.	$45.6M	— (loss-making)	— (loss-making)	−68.69% (below 0%: shrinking)	n/m	−201.65% (below 0%: shrinking)	33.58%	(138.86%)	Compare
TELA TELA Bio, Inc.	$45.6M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)	Compare
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
NNOX Nano-X Imaging Ltd.	$38.6M	— (loss-making)	— (loss-making)	+36.71% (above 0%: growing)	n/m	−21.37% (below 0%: shrinking)	(1,050.87%)	(1,334.91%)	Compare
CVRX CVRx, Inc.	$37.0M	— (loss-making)	— (loss-making)	+15.57% (above 0%: growing)	n/m	−11.18% (below 0%: shrinking)	87.39%	(82.92%)	Compare
Median of peers	$45.0M	—	—	−3.81%	—	−19.54%	53.18%	(102.81%)

All 149 Medical Devices stocks →

Xtant Medical Holdings, Inc. (XTNT) key facts

Strength: Xtant Medical Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $133.9 million, up 14.2% from fiscal 2024.
Xtant Medical Holdings, Inc. (XTNT) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, XTNT traded at $0.28, a market capitalization of $42.5 million.
Return on equity was 10.6% and debt-to-equity 0.57.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 0.03 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.